Cancer Treatment Reviews

Papers
(The H4-Index of Cancer Treatment Reviews is 39. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2020-11-01 to 2024-11-01.)
ArticleCitations
Association between immune-related side effects and efficacy and benefit of immune checkpoint inhibitors – A systematic review and meta-analysis221
MYC as a target for cancer treatment220
Adenocarcinoma spectrum lesions of the lung: Detection, pathology and treatment strategies140
Adjuvant and neoadjuvant breast cancer treatments: A systematic review of their effects on mortality127
Global challenges and policy solutions in breast cancer control117
Microsatellite instability in Gastric Cancer: Between lights and shadows112
Indoleamine 2,3-dioxygenase (IDO) inhibitors and cancer immunotherapy110
Targeting FGFR inhibition in cholangiocarcinoma109
Treatment landscape of metastatic pancreatic cancer107
BAP1: Not just a BRCA1-associated protein105
MEK inhibitor resistance mechanisms and recent developments in combination trials101
Combining antibody-drug conjugates with immunotherapy in solid tumors: current landscape and future perspectives90
Targeting ARID1A mutations in cancer86
EGFR exon 20 insertions in advanced non-small cell lung cancer: A new history begins83
Multidisciplinary clinical guidance on trastuzumab deruxtecan (T-DXd)–related interstitial lung disease/pneumonitis—Focus on proactive monitoring, diagnosis, and management82
NRAS mutant melanoma: Towards better therapies75
Immunotherapy in non-small cell lung cancer harbouring driver mutations66
Role of FGFR3 in bladder cancer: Treatment landscape and future challenges64
Locoregional therapies in patients with intrahepatic cholangiocarcinoma: A systematic review and pooled analysis60
Roadmap to cure multiple myeloma60
Integration of immunotherapy into treatment of cervical cancer: Recent data and ongoing trials58
Treatment strategies for patients with diffuse large B-cell lymphoma56
Targeting brain metastases in breast cancer55
Targeting HER2 heterogeneity in breast cancer54
Turning tumors from cold to inflamed to improve immunotherapy response53
Prognostic value of ctDNA detection in patients with early breast cancer undergoing neoadjuvant therapy: A systematic review and meta-analysis51
Peptide receptor radiotherapy re-treatment in patients with progressive neuroendocrine tumors: A systematic review and meta-analysis48
Cabozantinib: An evolving therapy for hepatocellular carcinoma47
Discordance of PD-L1 status between primary and metastatic breast cancer: A systematic review and meta-analysis47
Liquid biopsy in lymphoma: Molecular methods and clinical applications47
Sarcomas: Immune biomarker expression and checkpoint inhibitor trials47
The evolving panorama of HER2-targeted treatments in metastatic urothelial cancer: A systematic review and future perspectives46
KRAS Inhibitors– yes but what next? Direct targeting of KRAS– vaccines, adoptive T cell therapy and beyond45
A basic review on systemic treatment options in WHO grade II-III gliomas45
Blood biomarkers for differential diagnosis and early detection of pancreatic cancer44
Immune checkpoint Inhibitor–Induced diarrhea and Colitis: Incidence and Management. A systematic review and Meta-analysis44
Neurological complications of cancer immunotherapy42
A comprehensive overview of tumour deposits in colorectal cancer: Towards a next TNM classification41
Precision medicine in breast cancer: From clinical trials to clinical practice41
SELNET clinical practice guidelines for soft tissue sarcoma and GIST39
Current treatment and future challenges in ROS1- and ALK-rearranged advanced non-small cell lung cancer39
Metastatic colorectal cancer: Advances in the folate-fluoropyrimidine chemotherapy backbone39
0.083204984664917